Stada Gears Up For Higher-Strength Adalimumab As Alvotech Clears Up Legal Overhang
Iceandic Firm Has Settled European IP Disputes With Originator AbbVie
Executive Summary
Alvotech and its strategic partner Stada are preparing to launch their higher-strength adalimumab candidate AVT02 in Europe after settling intellectual property disputes with originator AbbVie.
You may also be interested in...
Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity
Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.
Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill
Legislation in development also could create an option for tentative approval of interchangeable biosimilars.
Shared First Interchangeable Biosimilar Exclusivity May Be Allowed Under US FDA User Fee Bill
Legislation in development also could create an option for tentative approval of interchangeable biosimilars.